Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities.
Pasin C, Nuñez DG, Kusejko K, Hachfeld A, Buvelot H, Cavassini M, Damonti L, Fux C, de Tejada BM, Notter J, Trkola A, Günthard HF, Aebi-Popp K, Kouyos RD, Abela IA; Swiss HIV Cohort Study. Pasin C, et al. Among authors: abela ia. HIV Med. 2024 Jun 3. doi: 10.1111/hiv.13677. Online ahead of print. HIV Med. 2024. PMID: 38830635
B-cell maturation antigen-directed bispecific antibodies in plasmablastic lymphoma.
Hofer KD, Wolfensberger N, Bachofner A, Schneidawind C, Stühler C, Bühler MM, Abela IA, Müller NJ, Zenz T, Manz MG, Rösler W, Khanna N, Schneidawind D. Hofer KD, et al. Among authors: abela ia. Br J Haematol. 2024 May 23. doi: 10.1111/bjh.19571. Online ahead of print. Br J Haematol. 2024. PMID: 38782604 No abstract available.
Circulating HBV RNA and hepatitis B core-related antigen trajectories in persons with HIV/HBV coinfection and HBsAg loss on tenofovir therapy.
Begré L, Boyd A, Plissonnier ML, Testoni B, Salazar-Vizcaya L, Suter-Riniker F, Scholtès C, Béguelin C, Rockstroh JK, Günthard HF, Calmy A, Cavassini M, Hirsch HH, Schmid P, Bernasconi E, Levrero M, Wandeler G, Zoulim F, Rauch A; Swiss HIV Cohort Study. Begré L, et al. J Infect Dis. 2024 Apr 16:jiae189. doi: 10.1093/infdis/jiae189. Online ahead of print. J Infect Dis. 2024. PMID: 38626170 Free article.
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Byonanebye DM, Polizzotto MN, Maltez F, Rauch A, Grabmeier-Pfistershammer K, Wit F, De Wit S, Castagna A, d'Arminio Monforte A, Mussini C, Wasmuth JC, Fontas E, Abela I, Sarcletti M, Bansi-Matharu L, Jaschinski N, Peters L, Hosein SR, Vannappagari V, Cohen C, Bissio E, Mocroft A, Law M, Ryom L, Petoumenos K; RESPOND study group. Byonanebye DM, et al. Among authors: abela i. Lancet HIV. 2024 May;11(5):e321-e332. doi: 10.1016/S2352-3018(23)00328-4. Epub 2024 Apr 12. Lancet HIV. 2024. PMID: 38621392
Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people with HIV.
Damas J, Munting A, Fellay J, Haerry D, Marzolini C, Tarr PE, Steffen A, Braun DL, Stoeckle M, Bernasconi E, Tshikung ON, Fux CA, Darling KEA, Béguelin C, Wandeler G, Cavassini M, Surial B; Swiss HIV Cohort Study (SHCS). Damas J, et al. Clin Infect Dis. 2024 Apr 12:ciae189. doi: 10.1093/cid/ciae189. Online ahead of print. Clin Infect Dis. 2024. PMID: 38606792 Free article.
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV.
Thoueille P, Saldanha SA, Schaller F, Choong E, Veuve F, Munting A, Cavassini M, Braun D, Günthard HF, Duran Ramirez JJ, Surial B, Furrer H, Rauch A, Ustero P, Calmy A, Stöckle M, Di Benedetto C, Bernasconi E, Schmid P, Marzolini C, Girardin FR, Buclin T, Decosterd LA, Guidi M; Swiss HIV Cohort Study. Thoueille P, et al. Clin Pharmacol Ther. 2024 Jun;115(6):1450-1459. doi: 10.1002/cpt.3240. Epub 2024 Mar 22. Clin Pharmacol Ther. 2024. PMID: 38519844 Free article.
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection.
Abela IA, Schwarzmüller M, Ulyte A, Radtke T, Haile SR, Ammann P, Raineri A, Rueegg S, Epp S, Berger C, Böni J, Manrique A, Audigé A, Huber M, Schreiber PW, Scheier T, Fehr J, Weber J, Rusert P, Günthard HF, Kouyos RD, Puhan MA, Kriemler S, Trkola A, Pasin C. Abela IA, et al. mBio. 2024 Feb 14;15(2):e0272223. doi: 10.1128/mbio.02722-23. Epub 2024 Jan 25. mBio. 2024. PMID: 38270455 Free PMC article.
Deciphering factors linked with reduced SARS-CoV-2 susceptibility in the Swiss HIV Cohort Study.
Abela IA, Hauser A, Schwarzmüller M, Pasin C, Kusejko K, Epp S, Cavassini M, Battegay M, Rauch A, Calmy A, Notter J, Bernasconi E, Fux CA, Leuzinger K, Perreau M, Ramette A, Gottschalk J, Schindler E, Wepf A, Marconato M, Manz MG, Frey BM, Braun DL, Huber M, Günthard HF, Trkola A, Kouyos RD; Swiss HIV Cohort Study. Abela IA, et al. J Infect Dis. 2024 Jan 16:jiae002. doi: 10.1093/infdis/jiae002. Online ahead of print. J Infect Dis. 2024. PMID: 38227786 Free article.
68 results